RxDoctor Payments DataLook up a doctor →

Whitfield Knapple, MD

Gastroenterology · North Little Rock, ARNPI 1912954504

Payments from drug & device makers

$3,138,442in general payments, 2019–2025

Across 442 payments — averaging $7100.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intercept Pharmaceuticals, Inc.$1.9M
  • Madrigal Pharmaceuticals$446K
  • Intercept Pharma Europe Ltd.$387K
  • Genentech, Inc.$125K
  • Bristol Myers Squibb$86K
  • Ferring Pharmaceuticals AS$76K
  • plus $75K from 15 others

What the payments were for

  • Food & beverage$4,65694%
  • Gifts$2906%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,138,442 in reported general payments places this provider in the 95th percentile of 108 gastroenterology providers in Arkansas.

See all gastroenterology providers in Arkansas

Medicare billing

Part B allowed, 2024
$213,550
Medicare patients
769
Services billed
2,797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab27$735,223
EntyvioVedolizumab21$181,171
LinzessLinaclotide70$61,244
CreonLipase/Protease/Amylase19$21,272
Budesonide DrBudesonide36$10,322
MotegrityPrucalopride Succinate17$8,920
Colestipol Hcl145$7,975
Ursodiol36$7,346
Pantoprazole Sodium549$5,225
Mesalamine28$5,008
Balsalazide Disodium27$3,685
Mesalamine ErMesalamine18$3,681
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl174$2,685
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl176$2,625
SutabSod Sulf/Pot Chloride/Mag Sulf16$2,621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$474$735,22327 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio, Motegrity$192$190,09138 claims
AbbVieLinzess, Creon$30,414$82,51689 claims
Braintree Laboratories, Inc.Sutab$290$2,62116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 108 gastroenterology providers in Arkansas.

Other gastroenterology in North Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →